Goodwin Biotechnology, Inc.

www.goodwinbio.com

Goodwin Biotechnology, Inc. (GBI), based near Fort Lauderdale, Florida, is a fully integrated, customer-focused cGMP Contract Manufacturing Organization (CMO) of Biosimilar and innovative monoclonal antibodies, recombinant proteins, vaccines, Antibody Drug Conjugates (ADCs) and other bioconjugates.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

DENOVO BIOPHARMA ANNOUNCES BREAKTHROUGH DISCOVERY OF A NOVEL GENETIC BIOMARKER FOR DB104 (LIAFENSINE) FOR DEPRESSION

BioSpace | March 12, 2020

news image

Denovo Biopharma LLC LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has successfully discovered a novel genetic biomarker associated with DB104 response to treat depression using its proprietary biomarker discovery platform. DB104 was licensed from Albany Molecular Research, Inc. following its return from Bristol-Myers Squibb, who had conducted two phase 2b clinical trials in treatment-resistant depression with this first-in-class triple reuptak...

Read More

Industrial Impact

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS

Navrogen Inc. | August 18, 2021

news image

Navrogen Inc. a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Tavotek Biotherapeutics, a biotech company focusing on novel multi-specific antibodies in immuno-oncology and autoimmune diseases, announced today that they have entered into a strategic collaboration to identify and develop experimental monoclonal antibodies (mAbs) for the treatment of various cancer indications. Under the agreement, Navrogen and Tavotek will...

Read More

MedTech

BIONAUT LABS CLOSES $43M IN SERIES B LED BY KHOSLA VENTURES TO ADVANCE FIRST-IN-CLASS MICRO-ROBOTIC TECHNOLOGY AND REMOVE BARRIERS

Bionaut Labs | November 29, 2022

news image

Bionaut Labs, the company that uses microscale robots to revolutionize the treatment of central nervous system diseases and disorders, announced $43.2M in a Series B round of financing led by Khosla Ventures, bringing the company’s total financing raised to date to $63.2 million. Also participating in the round are new investors Deep Insight, OurCrowd, PSPRS, Sixty Degree Capital, Dolby Family Ventures, GISEV Family Ventures, What if Ventures, Tintah Grace and Gaingels, along with all exis...

Read More

Medical

TAIWAN STARTUP MOLSENTECH ULTRA-HIGH SENSITIVITY BIOMEDICAL DETECTION TECHNOLOGY LEAPS ONTO GLOBAL STAGE

Molsentech | July 29, 2022

news image

With its impressive achievements, Molsentech has been selected by the TTA Global Challenge sponsored by Taiwan's Ministry of Science and Technology to participate in US BIO 2022, poised to leverage its introduction to the US market as a stepping stone to leap further into the global stage. The company has successfully launched an electrical based detection system employing ultra-high sensitivity biomedical detection technology that can be applied in various disease detection from an early st...

Read More
news image

DENOVO BIOPHARMA ANNOUNCES BREAKTHROUGH DISCOVERY OF A NOVEL GENETIC BIOMARKER FOR DB104 (LIAFENSINE) FOR DEPRESSION

BioSpace | March 12, 2020

Denovo Biopharma LLC LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it has successfully discovered a novel genetic biomarker associated with DB104 response to treat depression using its proprietary biomarker discovery platform. DB104 was licensed from Albany Molecular Research, Inc. following its return from Bristol-Myers Squibb, who had conducted two phase 2b clinical trials in treatment-resistant depression with this first-in-class triple reuptak...

Read More
news image

Industrial Impact

NAVROGEN INC. AND TAVOTEK BIOTHERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO IMPROVE THERAPEUTIC EFFICACY OF ANTIBODY PIPELINE AGENTS

Navrogen Inc. | August 18, 2021

Navrogen Inc. a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Tavotek Biotherapeutics, a biotech company focusing on novel multi-specific antibodies in immuno-oncology and autoimmune diseases, announced today that they have entered into a strategic collaboration to identify and develop experimental monoclonal antibodies (mAbs) for the treatment of various cancer indications. Under the agreement, Navrogen and Tavotek will...

Read More
news image

MedTech

BIONAUT LABS CLOSES $43M IN SERIES B LED BY KHOSLA VENTURES TO ADVANCE FIRST-IN-CLASS MICRO-ROBOTIC TECHNOLOGY AND REMOVE BARRIERS

Bionaut Labs | November 29, 2022

Bionaut Labs, the company that uses microscale robots to revolutionize the treatment of central nervous system diseases and disorders, announced $43.2M in a Series B round of financing led by Khosla Ventures, bringing the company’s total financing raised to date to $63.2 million. Also participating in the round are new investors Deep Insight, OurCrowd, PSPRS, Sixty Degree Capital, Dolby Family Ventures, GISEV Family Ventures, What if Ventures, Tintah Grace and Gaingels, along with all exis...

Read More
news image

Medical

TAIWAN STARTUP MOLSENTECH ULTRA-HIGH SENSITIVITY BIOMEDICAL DETECTION TECHNOLOGY LEAPS ONTO GLOBAL STAGE

Molsentech | July 29, 2022

With its impressive achievements, Molsentech has been selected by the TTA Global Challenge sponsored by Taiwan's Ministry of Science and Technology to participate in US BIO 2022, poised to leverage its introduction to the US market as a stepping stone to leap further into the global stage. The company has successfully launched an electrical based detection system employing ultra-high sensitivity biomedical detection technology that can be applied in various disease detection from an early st...

Read More

Resources

resource image

Cell and Gene Therapy, Industrial Impact

Single-cell RNA Sequencing and Analysis

Video

resource image

Cell and Gene Therapy, Industrial Impact

GMP Grade PMSF and Protease Inhibitors

Whitepaper

resource image

Cell and Gene Therapy, MedTech

Multi-Specific Monoclonal Antibodies

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Single-cell RNA Sequencing and Analysis

Video

resource image

Cell and Gene Therapy, Industrial Impact

GMP Grade PMSF and Protease Inhibitors

Whitepaper

resource image

Cell and Gene Therapy, MedTech

Multi-Specific Monoclonal Antibodies

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us